Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of miRNA modulators to PARP inhibitor response.
Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A. Neijenhuis S, et al. DNA Repair (Amst). 2013 Jun 1;12(6):394-402. doi: 10.1016/j.dnarep.2013.02.003. Epub 2013 Apr 6. DNA Repair (Amst). 2013. PMID: 23570906
The current state of pemetrexed in ovarian cancer.
Miller RE, Banerjee S. Miller RE, et al. Expert Opin Investig Drugs. 2013 Sep;22(9):1201-10. doi: 10.1517/13543784.2013.820703. Epub 2013 Jul 31. Expert Opin Investig Drugs. 2013. PMID: 23899335 Review.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Bajrami I, et al. Among authors: miller re. Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15. Cancer Res. 2014. PMID: 24240700 Free PMC article.
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1); Singh N. Cohen PA, et al. Gynecol Oncol. 2019 Aug;154(2):441-448. doi: 10.1016/j.ygyno.2019.04.679. Epub 2019 May 19. Gynecol Oncol. 2019. PMID: 31118141 Free article. Review.
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R, Hall M, Lofts F, Glasspool RM, Hudson E. Lord R, et al. Int J Gynecol Cancer. 2020 Jul;30(7):1026-1033. doi: 10.1136/ijgc-2019-000973. Epub 2020 Apr 21. Int J Gynecol Cancer. 2020. PMID: 32321768
720 results